Folylpoly-γ-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 942-951

  Leclerc, Guy J ^a   Barredo, Julio C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLYLPOLYGLUTAMATE SYNTHASE; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; FOLATE METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALTERNATIVE SPLICING; BONE MARROW CELLS; CATALYSIS; CELL LINE; EXONS; FETUS; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; PEPTIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0034910313     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Enzymatic synthesis and function of folylpolyglutamates
2. Enzymatic synthesis of folylpolyglutamate synthetase: Characterization of the reaction and its products
3. Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetase
4. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism
5. Role of folylpolyglutamate synthetase (FPGS) in antifolate chemotherapy: A biochemical and clinical update
6. Structural features of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase
7. ICI D1694, a quinazoline antifolate thymidylate synthetase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study
8. Determinants of antifolate cytotoxicity: Folylpolyglutamate synthetase activity during cellular proliferation and development
9. Differences is constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia
10. Rapid decline in folylpolyglutamate synthetase activity and gene expression during maturation of HL-60 cells
11. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity
12. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity
13. Folypolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo
14. Decreased folypolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines
15. Impaired polyglutamylation of methotrexate as a cause of resistance on CCRF-CEM cells after short-term, high dose treatment with this drug
16. Upstream organization of and multiple transcripts from the human folylpoly-γ-glutamate synthetase gene
17. Expression cloning of a human cDNA encoding folylpoly (γ-glutamate) synthetase and determination of its primary structure
18. Tissue-specific expression of functional isoforms of mouse folylpoly-γ-glutamate synthetase: A basis for targeting folate antimetabolites
19. Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization, and differential splicing of its gene
20. Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by polymerase chain reaction: Marked variation of expression among leukemia patients
21. Folylpolyglutamate synthetase expression in antifolate-sensitive and-resistant human cell lines
22. Polyglutamation of methotrexate. Is methotrexate a prodrug?
23. Additional organizational features of the murine folylpolyglutamate synthetase gene. Two remotely situated exons encoding an alternate 5′-end and proximal open reading frame under the control of a second promoter
24. Aberrant splicing but not mutations of TG101 in human breast cancer
25. Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer
26. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer
27. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure
28. Measurement of folylpolyglutamate synthetase in mammalian tissues
29. A microassay for mammalian folylpolyglutamate synthetase